International Journal of Clinical Oncology

, Volume 22, Issue 1, pp 181–189 | Cite as

Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma

  • Shinya Morita
  • Yuji Nakamaru
  • Akihiro HommaEmail author
  • Shinichiro Yasukawa
  • Hiromitsu Hatakeyama
  • Tomohiro Sakashita
  • Satoshi Kano
  • Atsushi Fukuda
  • Satoshi Fukuda
Original Article



The aim of this study was to investigate the expression of p53, p16, cyclin D1, epidermal growth factor receptor (EGFR) and Notch1 in temporal bone squamous cell carcinoma (TBSCC) tissue samples by immunohistochemistry (IHC), and to evaluate the association between these biomarkers and clinicopathological features.


We performed a retrospective, single-institution review of 30 TBSCC patients treated with curative intent between April 2006 and March 2015. All tissue samples were obtained from pretreatment biopsy specimens or surgical specimens and using IHC staining.


Ten patients were categorized as T1, seven as T2, five as T3 and eight as T4. Nine patients had clinically positive lymph node metastasis. The positive expression of p53 and EGFR was significantly associated with T classification (P = 0.042 and P = 0.0039). EGFR expression was significantly more frequent in patients with positive lymph node metastasis compared with patients without node involvement (P = 0.017). In the analysis of the association between protein expression by IHC staining and prognosis, the positive expression of EGFR and Notch1 was significantly correlated with poor survival outcomes in TBSCC (P = 0.015 and P = 0.025)


Overexpression of p53 and EGFR may be valuable biomarkers for identifying individuals at high risk of developing tumors in TBSCC. Furthermore, the positive expression of EGFR was significantly associated with poor survival outcome. Anti-EGFR therapy has potential for use as the treatment modality of choice for advanced-stage TBSCC as well as other head and neck squamous cell carcinomas.


Temporal bone squamous cell carcinoma Clinicopathological features EGFR Protein expression Immunohistochemistry Prognostic factor 



This study received financial support from a Health and Labour Sciences Research Grant for Clinical Cancer Research (H26-141) from the Ministry of Health, Labour and Welfare of Japan, and the National Cancer Center Research and Development Fund (26-A-4) of Japan.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Yin M, Ishikawa K, Honda K et al (2006) Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx 33:251–257CrossRefPubMedGoogle Scholar
  2. 2.
    Moody SA, Hirsch BE, Myers EN (2000) Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol 21:582–588PubMedGoogle Scholar
  3. 3.
    Ito M, Hatano M, Yoshizaki T (2009) Prognostic factors for squamous cell carcinoma of the temporal bone: extensive bone involvement or extensive soft tissue involvement? Acta Otolaryngol 129:1313–1319CrossRefPubMedGoogle Scholar
  4. 4.
    Kropveld A, Slootweg PJ, van Mansfeld AD et al (1996) Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 78:991–997CrossRefPubMedGoogle Scholar
  5. 5.
    Shin DM, Lee JS, Lippman SM et al (1996) p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519–529CrossRefPubMedGoogle Scholar
  6. 6.
    Gasparini G, Bevilacqua P, Bonoldi E et al (1995) Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1:1375–1383PubMedGoogle Scholar
  7. 7.
    Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMedGoogle Scholar
  8. 8.
    Agrawal N, Frederick MJ, Pickering CR et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154–1157CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gursel DB, Berry N, Boockvar JA (2012) The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery 70:N19–N21CrossRefPubMedGoogle Scholar
  10. 10.
    Yabuuchi S, Pai SG, Campbell NR et al (2013) Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335:41–51CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lee HJ, Kang YH, Lee JS et al (2015) Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health 15:153CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sato-Kuwabara Y, Fregnani JH, Jampietro J et al (2016) Comparative analysis of basaloid and conventional squamous cell carcinomas of the esophagus: prognostic relevance of clinicopathological features and protein expression. Tumour Biol 37:6691–6699CrossRefPubMedGoogle Scholar
  13. 13.
    Sakashita T, Homma A, Suzuki S et al (2013) Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas. Acta Otolaryngol 133:984–991CrossRefPubMedGoogle Scholar
  14. 14.
    Chu D, Zhou Y, Zhang Z et al (2011) Notch1 expression, which is related to p65 status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res 17:5686–5694CrossRefPubMedGoogle Scholar
  15. 15.
    Takenaka Y, Cho H, Nakahara S et al (2015) Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: a meta-analysis. Head Neck 37:1073–1080CrossRefPubMedGoogle Scholar
  16. 16.
    Sweeny L, Dean NR, Magnuson JS et al (2012) EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 34:681–686CrossRefPubMedGoogle Scholar
  17. 17.
    Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453–456CrossRefPubMedGoogle Scholar
  18. 18.
    Marchetti P, Cannita K, Ricevuto E et al (2003) Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol 14:704–708CrossRefPubMedGoogle Scholar
  19. 19.
    Karpathiou G, Monaya A, Forest F et al (2016) p16 and p53 expression status in head and neck squamous cell carcinoma: a correlation with histological, histoprognostic and clinical parameters. Pathology 48:341–348CrossRefPubMedGoogle Scholar
  20. 20.
    Zambetti GP (2007) The p53 mutation “gradient effect” and its clinical implications. J Cell Physiol 213:370–373CrossRefPubMedGoogle Scholar
  21. 21.
    Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26CrossRefPubMedGoogle Scholar
  22. 22.
    Nyrop M, Grontved A (2002) Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg 128:834–837CrossRefPubMedGoogle Scholar
  23. 23.
    Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–1354CrossRefPubMedGoogle Scholar
  24. 24.
    Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584PubMedGoogle Scholar
  25. 25.
    Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamics properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30:255–268CrossRefPubMedGoogle Scholar
  26. 26.
    Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMedGoogle Scholar
  27. 27.
    Langer CJ (2012) Exploring biomarkers in head and neck cancer. Cancer 118:3882–3892CrossRefPubMedGoogle Scholar
  28. 28.
    Shao H, Huang Q, Liu ZJ (2012) Targeting notch signaling for cancer therapeutic intervention. Adv Pharmacol 65:191–234CrossRefPubMedGoogle Scholar
  29. 29.
    Ai Q, Ma X, Huang Q et al (2012) High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One 7:e35022CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhou L, Zhang N, Song W et al (2013) The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One 8:e57382CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lin JT, Chen MK, Yeh KT et al (2010) Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol 17:2976–2983CrossRefPubMedGoogle Scholar
  32. 32.
    Valgardsdottir R, Tryggvadottir L, Steinarsdottir M et al (1997) Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105:121–130CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2016

Authors and Affiliations

  • Shinya Morita
    • 1
  • Yuji Nakamaru
    • 1
  • Akihiro Homma
    • 1
    Email author
  • Shinichiro Yasukawa
    • 2
  • Hiromitsu Hatakeyama
    • 1
  • Tomohiro Sakashita
    • 1
  • Satoshi Kano
    • 1
  • Atsushi Fukuda
    • 1
  • Satoshi Fukuda
    • 1
  1. 1.Department of Otolaryngology-Head and Neck SurgeryHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Department of Translational PathologyHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations